CALR mutation: Definition, Uses, and Clinical Overview

Posted on February 27, 2026 | by drcancer

CALR mutation Introduction (What it is)

CALR mutation is a change in the CALR (calreticulin) gene found in some blood cancers.
It most often comes up when clinicians evaluate myeloproliferative neoplasms (MPNs), which are cancers where the bone marrow makes too many blood cells.
CALR mutation testing is typically done on blood or bone marrow samples.
Results help clinicians classify disease and guide overall care planning.

Why CALR mutation used (Purpose / benefits)

CALR mutation is used primarily as a diagnostic and disease-classification marker in hematology-oncology. In patients with persistently abnormal blood counts—especially high platelets (thrombocytosis)—clinicians often need to determine whether the pattern is due to a reactive (non-cancer) cause (such as inflammation or iron deficiency) or an underlying clonal bone marrow disorder like an MPN.

Key purposes and benefits include:

Supporting an MPN diagnosis: CALR mutation is one of the main “driver” mutations in certain MPNs, particularly essential thrombocythemia (ET) and primary myelofibrosis (PMF). Detecting it can strengthen the case that blood count abnormalities reflect a clonal process.
Helping classify MPN subtype: Along with clinical findings, blood counts, and bone marrow morphology (how marrow cells look under the microscope), CALR mutation status can contribute to distinguishing ET from PMF and related conditions.
Risk context and prognosis: In many care settings, mutation status (CALR vs other mutations) is considered alongside age, symptoms, blood counts, bone marrow findings, and other lab results to estimate risk and plan monitoring. Prognostic implications vary by cancer type and stage and by the overall clinical picture.
Guiding further testing: A positive CALR mutation may reduce the need for repeatedly searching for other driver mutations, while a negative result may prompt broader genetic panels or more emphasis on non-genetic diagnostic criteria.
Establishing a molecular baseline: When a mutation is identified, it can serve as a reference point for future evaluations if the disease course changes or if advanced testing is considered.

Indications (When oncology clinicians use it)

Clinicians commonly consider CALR mutation testing in scenarios such as:

Persistent thrombocytosis with no clear reactive cause
Suspected essential thrombocythemia (ET)
Suspected primary myelofibrosis (PMF), including “prefibrotic” presentations assessed by marrow examination
An MPN workup when JAK2 mutation testing is negative or when a broader driver-mutation assessment is planned
Unexplained splenomegaly (enlarged spleen) with blood count abnormalities suggestive of an MPN
Bone marrow biopsy findings that raise concern for an MPN and require molecular support for classification
Reassessment of diagnosis when clinical features evolve over time (for example, changing blood counts or increasing symptoms)

Contraindications / when it’s NOT ideal

CALR mutation is a test result, not a treatment, so “contraindications” mainly relate to when testing is unlikely to be useful or when another approach may be more appropriate:

Clear alternative explanation for blood count changes: If thrombocytosis is clearly reactive (for example, acute infection) and normalizes with time, clinicians may prioritize treating and reassessing the underlying cause before molecular testing.
MPN types where CALR is uncommon: In some suspected conditions, other molecular tests may be prioritized based on typical disease biology (the best initial test can vary by clinician and case).
Inadequate or poor-quality sample: Low DNA yield, hemodiluted marrow aspirate, or improper handling can reduce test reliability and may require repeat sampling.
Very low disease burden or borderline abnormalities: When the pre-test probability is low, clinicians may choose observation and repeat labs rather than immediate molecular testing.
Situations requiring broader genomic profiling: If there is concern for a more complex hematologic malignancy, clinicians may prefer a next-generation sequencing (NGS) panel rather than a single-gene test.
Unclear clinical question: Ordering mutation testing without a defined diagnostic or management question can lead to ambiguous interpretation and unnecessary anxiety.

How it works (Mechanism / physiology)

CALR mutation is most relevant to bone marrow biology and the regulation of blood cell production.

Clinical pathway (diagnostic)

The mutation is detected by laboratory methods (commonly PCR-based assays or NGS) using peripheral blood or bone marrow.
The result is interpreted alongside clinical findings (symptoms, spleen size), blood counts, and bone marrow morphology to help diagnose and classify MPNs.

Tumor biology and tissue involved

The CALR gene encodes calreticulin, a protein normally involved in cellular functions including protein folding and calcium regulation in the endoplasmic reticulum.
In MPNs, many CALR mutations are frameshift mutations (often in exon 9) that alter the protein’s tail end. This altered protein is associated with abnormal signaling that promotes overproduction of certain blood cell lineages, especially megakaryocytes (platelet-forming cells).
A commonly described downstream effect in CALR-mutated MPNs is abnormal activation of signaling pathways involved in blood cell growth (often discussed in relation to the JAK-STAT pathway). The exact biologic behavior can differ across patients and disease subtypes.

Onset, duration, and reversibility

CALR mutation is a molecular finding, not a therapy, so “onset” and “duration” do not apply in the same way as for drugs or radiation.
In most MPN contexts, CALR mutations are considered somatic (acquired in marrow cells over time) rather than inherited. Whether a mutation burden changes over time can vary by clinician and case, the testing method used, and the disease course.

CALR mutation Procedure overview (How it’s applied)

CALR mutation is not a procedure or treatment. It is used as part of a diagnostic workflow in suspected MPNs. A typical high-level sequence may look like this:

Evaluation/exam – Review of symptoms (fatigue, headaches, itching, night sweats), history of clotting or bleeding, and physical exam (including spleen size when relevant).
Labs – Complete blood count (CBC) trends over time, peripheral smear review, iron studies or inflammatory markers if reactive causes are suspected, and other standard labs based on symptoms.
Imaging and/or biopsy (when needed) – Imaging may be used to assess spleen size in selected cases. – Bone marrow biopsy may be performed to evaluate marrow architecture, fibrosis, and cell lineages.
Molecular testing – Driver mutation testing may include JAK2, CALR, and MPL, sometimes as sequential tests and sometimes as a panel. – Some patients also undergo broader NGS panels to look for additional mutations relevant to prognosis or classification.
Staging / risk assessment (conceptual in MPNs) – Many MPNs are not staged like solid tumors; instead, clinicians often use risk stratification based on factors such as age, prior thrombosis, symptoms, blood counts, and marrow findings. How CALR mutation is weighted varies by cancer type and stage and by the risk model used.
Treatment planning – If an MPN is diagnosed, options may include observation, medications to control counts or symptoms, and supportive care strategies. Mutation status can be one part of the overall context.
Response assessment and follow-up – Ongoing monitoring typically includes symptom review and repeat blood counts, with additional testing based on clinical changes.

Types / variations

“Types” of CALR mutation usually refers to specific mutation patterns and to testing approaches.

Common mutation patterns

Type 1 and type 2 CALR mutation: These labels are commonly used to describe frequent frameshift variants (often within exon 9) seen in MPNs. They may be associated with different clinical patterns across ET and PMF cohorts, but individual outcomes vary by clinician and case and depend on multiple factors beyond mutation type.
Other CALR variants: Less common insertions/deletions and rarer variants can occur. Some may be harder to detect depending on the assay.

Testing approaches

Single-gene testing: Focused testing for CALR mutations may be ordered when the clinical suspicion is specific (for example, suspected ET with JAK2-negative results).
Driver mutation panels: CALR may be tested alongside JAK2 and MPL as part of a standard MPN driver set.
Broader NGS panels: These may evaluate CALR plus additional genes that can contribute to diagnosis, prognosis, or differential diagnosis (for example, to assess other myeloid neoplasms).

Care settings

Outpatient hematology clinics: Most CALR testing is ordered and reviewed in outpatient settings.
Inpatient setting: Testing may be initiated in hospitalized patients when blood counts are markedly abnormal or when complications (such as thrombosis) prompt evaluation.

Pros and cons

Pros:

Helps support diagnosis of certain myeloproliferative neoplasms, especially ET and PMF
Provides a molecular explanation for otherwise unexplained thrombocytosis in appropriate clinical contexts
Can reduce diagnostic uncertainty when paired with marrow findings and blood counts
May help clinicians frame risk discussions and follow-up intensity in some care models
Offers a baseline molecular marker that can be referenced if the clinical course changes
Testing can often be performed on a blood sample, avoiding invasive sampling in some cases

Cons:

A positive result does not, by itself, determine the exact diagnosis or best management plan
A negative result does not rule out MPNs; some patients have other mutations or “triple-negative” disease
Interpretation depends heavily on clinical context and may require specialist input
Test sensitivity and reporting can vary by assay (PCR vs NGS) and by sample quality
Results can cause anxiety if patients assume “mutation” automatically equals aggressive cancer
Insurance coverage and access to molecular testing can vary by location and health system

Aftercare & longevity

CALR mutation itself does not require aftercare, but a CALR-mutated MPN diagnosis often leads to structured follow-up. Long-term outlook is influenced by multiple factors, and outcomes vary by cancer type and stage and by individual biology.

Common factors that affect monitoring plans and longer-term course include:

MPN subtype and disease burden: ET and PMF can have different symptom patterns, risks, and monitoring needs.
Blood count control and symptom burden: Clinicians track platelet count, hemoglobin, white blood cell count, and symptoms over time, adjusting care as needed.
Risk of thrombosis or bleeding: MPNs can be associated with clotting or bleeding risks, and follow-up often centers on prevention and early recognition of complications (the approach varies by clinician and case).
Bone marrow changes over time: In some patients, marrow fibrosis or other features may evolve, which can prompt reassessment of diagnosis and management.
Comorbidities and medications: Other health conditions, smoking status, mobility, and concurrent medications can influence overall risk and tolerance of therapies.
Supportive care and survivorship services: Symptom management, fatigue support, mental health care, and rehabilitation services can affect quality of life and function.
Access to specialty care and monitoring: Regular follow-ups and timely evaluation of new symptoms can influence outcomes, especially when complications arise.

Alternatives / comparisons

CALR mutation testing is one tool among several used in evaluating suspected MPNs and related conditions. Alternatives and complementary approaches include:

Observation and repeat labs (watchful waiting): For mild or transient platelet elevations, clinicians may repeat CBCs and evaluate for reactive causes before ordering molecular tests.
Testing for other driver mutations (JAK2, MPL): These are commonly assessed in parallel or sequence with CALR in MPN workups. Which test is prioritized can depend on the suspected diagnosis and local practice.
Bone marrow biopsy vs molecular testing: A bone marrow biopsy provides architecture and fibrosis information that a blood-based mutation test cannot. Conversely, mutation testing provides molecular evidence that morphology alone may not confirm.
Cytogenetics and broader NGS panels: If the presentation is atypical or suggests a more complex myeloid disorder, broader testing can provide additional diagnostic and prognostic context beyond CALR alone.
Standard care vs clinical trials (where appropriate): For patients with symptomatic or higher-risk disease, clinical trials may be considered depending on diagnosis, prior therapy, and eligibility. Trial availability and suitability vary by center and case.

CALR mutation Common questions (FAQ)

Q: What does a CALR mutation result mean in plain language?
It means a change was found in the CALR gene in blood-forming cells. In the right clinical setting, this supports the possibility of a myeloproliferative neoplasm such as essential thrombocythemia or primary myelofibrosis. The result is interpreted together with blood counts, symptoms, and sometimes bone marrow findings.

Q: Is CALR mutation inherited or something I was born with?
In most MPN evaluations, CALR mutations are considered somatic, meaning they arise in certain cells over time rather than being inherited from a parent. Whether genetic counseling is needed depends on the broader personal and family history. Your clinician may clarify what type of testing was performed (somatic vs germline).

Q: How is CALR mutation testing done—does it hurt?
Testing is often done on a blood draw, which typically causes brief discomfort similar to other blood tests. Some patients have testing done on bone marrow samples if a biopsy is part of the diagnostic workup. Bone marrow biopsy discomfort varies, and local anesthesia is commonly used.

Q: Do I need anesthesia for testing?
A standard blood draw does not require anesthesia. A bone marrow biopsy is usually done with local numbing medication, and some centers offer additional sedation depending on the setting and patient needs. Availability and approach vary by facility.

Q: How long does it take to get results?
Turnaround time depends on the laboratory method and whether testing is sent to an external lab. Some assays are reported faster than broad NGS panels. Your care team can explain typical timelines at their institution.

Q: Does having a CALR mutation tell me what treatment I need?
Not on its own. CALR mutation status is one factor among many, including symptoms, blood counts, prior clotting history, marrow findings, and overall health. Treatment planning is individualized and varies by clinician and case.

Q: Are there side effects from CALR mutation testing?
The test itself is performed on a sample, so side effects relate to how the sample is collected. Blood draws can cause bruising or lightheadedness in some people. Bone marrow biopsy can cause temporary soreness and, rarely, bleeding or infection.

Q: Will CALR mutation affect my ability to work or exercise?
The mutation result itself does not limit activity. Activity recommendations depend on the underlying condition, symptoms (such as fatigue), blood counts, and any complications like clotting or bleeding risks. Clinicians may tailor guidance to the individual situation.

Q: What about fertility and pregnancy concerns?
CALR mutation status can be part of an MPN diagnosis, and fertility or pregnancy considerations usually relate to the disease and its treatments, not the mutation alone. Planning can involve hematology and obstetric specialists when relevant. The safest approach varies by clinician and case.

Q: What follow-up is typical after a CALR mutation is found?
Follow-up commonly includes periodic blood counts, symptom assessment, and review of any clotting or bleeding events. Some patients also have periodic imaging or repeat marrow evaluation if clinically indicated. The schedule depends on diagnosis, risk category, and how stable the condition is over time.